KR100377313B1 - Method Of Fabricating Green tea Extractive - Google Patents
Method Of Fabricating Green tea Extractive Download PDFInfo
- Publication number
- KR100377313B1 KR100377313B1 KR10-2000-0014644A KR20000014644A KR100377313B1 KR 100377313 B1 KR100377313 B1 KR 100377313B1 KR 20000014644 A KR20000014644 A KR 20000014644A KR 100377313 B1 KR100377313 B1 KR 100377313B1
- Authority
- KR
- South Korea
- Prior art keywords
- green tea
- tea extract
- blood
- extract
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/16—Tea extraction; Tea extracts; Treating tea extract; Making instant tea
- A23F3/30—Further treatment of dried tea extract; Preparations produced thereby, e.g. instant tea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medical Informatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명은 녹차로부터 추출된 성분을 제제화함으로써, 당뇨병, 비만, 고지혈증, 고콜레스테롤혈증을 치료할 수 있는 녹차 추출물의 제조방법에 관한 것이다.The present invention relates to a method for preparing green tea extracts which can treat diabetes, obesity, hyperlipidemia and hypercholesterolemia by formulating components extracted from green tea.
본 발명에 따른 녹차추출물의 제조방법은 건조녹차잎 분말 1 중량부에 5 내지 20 중량부의 증류수를 가하여 60~110℃의 열수에서 15분이상 가열하는 단계와, 녹차잎 분말을 감압여과에 의해 제거하고 4℃로 냉각한 후 침전물을 감압여과하여 녹차추출액을 형성하는 단계와, 녹차추출액을 분무건조 및 분쇄하는 단계와, 녹차 추출물에 에틸 에테르를 가하고 교반하여 에테르층을 제거하는 단계를 포함하는 것을 특징으로 한다.Method for producing a green tea extract according to the present invention by adding 5 to 20 parts by weight of distilled water to 1 part of dry green tea leaf powder and heating for 15 minutes or more in hot water of 60 ~ 110 ℃, removing the green tea leaf powder by vacuum filtration And cooling the mixture to 4 ° C. and filtering the precipitate under reduced pressure to form green tea extract, spray drying and pulverizing the green tea extract, adding ethyl ether to green tea extract and stirring to remove the ether layer. It features.
Description
본 발명은 녹차(학명: Camellia sinensis)로부터 추출된 성분을 제제화함으로써, 당뇨병, 비만, 고지혈증, 고콜레스테롤혈증을 치료할 수 있는 녹차 추출물의 제조방법에 관한 것이다.The present invention relates to a method for preparing a green tea extract that can treat diabetes, obesity, hyperlipidemia, hypercholesterolemia by formulating a component extracted from green tea (Camellia sinensis).
종전부터 차로서의 녹차가 당뇨 및 비만에 효과가 있다고 민간에서 알려져 있었으나, 녹차에서 추출한 물질의 당뇨병이나 비만에 대한 효과에 관한 구체적이고 과학적인 연구는 이제까지 보고된 바가 없다.It has been known in the folklore that green tea as a tea has an effect on diabetes and obesity, but no specific scientific studies on the effects of green tea extracts on diabetes or obesity have been reported.
일반적으로 기호식품으로서의 차를 만들 때는 60 내지 80℃ 온도의 물에 녹차를 3 내지 5분 정도 우려내어 음용하였다. 그러나, 본 제제의 주성분인 폴리페놀(polyphenol)은 유리되는데 더 많은 시간을 요하므로, 본 발명에서는 녹차에 함유된 의학적으로 유용한 성분을 추출해 내기 위한 방법을 연구하였다.In general, when making tea as a favorite food, green tea was brewed in water at a temperature of 60 to 80 ° C. for 3 to 5 minutes, and drinking. However, since polyphenol, which is a main component of the present formulation, requires more time to be released, the present invention has studied a method for extracting a medically useful component contained in green tea.
당뇨병 치료제로 이용되고 있는 제제는 당의 체내 이용을 증가시키는 제제와 당의 흡수량을 저하시키는 제제가 있다. 전분은 소화효소인 아밀라제에 의해서 이당류나 삼당류로 분해되고 이들은 소장 내의 이당류 분해효소인 알파글리코시다제에 의해서 단당류인 포도당으로 분해되어 흡수된다.Agents used in the treatment of diabetes mellitus include agents that increase the use of sugar in the body and agents that lower the absorption of sugar. Starch is broken down into disaccharides and trisaccharides by amylase, a digestive enzyme, and they are broken down and absorbed into glucose, a monosaccharide, by alphaglycosidase, a disaccharide enzyme in the small intestine.
현재, 이당류의 분해효소인 알파글리코시다제를 억제시키는 제제인 아카보스가 당뇨병의 치료에서 혈당 강하제로 이용되고 있다. 그러나, 식사후 아카보스를 복용하면 아밀라제에 의해서 전분이 이당류로 분해되나 알파글리코시다제가 억제되어 장내에 이당류의 농도가 증가된다. 장내 이당류의 농도 증가는 삼투압 증가로 인한 설사가 유발될 수 있고, 장내 세균에 의해서 이당류가 분해되면서 생성되는 개스량이 증가되는 등의 부작용을 가지고 있다. 또한 혈당강하제나 당뇨병치료제로서 아밀라제 억제제가 상품화된 예는 현재까지 없다.Currently, acarbose, an agent that inhibits alphaglycosidase, a disaccharide degrading enzyme, is used as a hypoglycemic agent in the treatment of diabetes. However, taking acabose after a meal breaks down starch into disaccharides by amylase, but inhibits alphaglycosidase and increases the concentration of disaccharides in the intestine. Increasing the concentration of intestinal disaccharides may cause diarrhea due to an increase in osmotic pressure, and has an adverse effect such as an increase in the amount of gas produced as the disaccharides are degraded by the intestinal bacteria. In addition, there are no examples of commercialization of amylase inhibitors as hypoglycemic agents or diabetes treatments.
본 발명은 녹차로부터 추출된 성분을 제제화함으로써, 당뇨병, 비만, 고지혈증, 고콜레스테롤혈증을 치료할 수 있는 녹차 추출물의 제조방법을 제공하고자 한다.The present invention is to provide a method for preparing a green tea extract that can treat diabetes, obesity, hyperlipidemia, hypercholesterolemia by formulating components extracted from green tea.
즉, 본 발명에 따르면, 건조녹차잎 분말 1 중량부에 5 내지 20 중량부의 증류수를 가하여 60~110℃의 열수에서 15분이상 가열하는 단계와, 녹차잎 분말을 감압여과에 의해 제거하고 4℃로 냉각한 후 침전물을 감압여과하여 녹차추출액을 형성하는 단계와, 녹차추출액을 분무건조 및 분쇄하는 단계와, 녹차 추출물에 에틸 에테르를 가하고 교반하여 에테르층을 제거하는 단계를 포함하는 것을 특징으로 하는 녹차 추출물의 제조방법이 제공된다.That is, according to the present invention, by adding 5 to 20 parts by weight of distilled water to 1 part of dry green tea leaf powder and heating at 60 to 110 ℃ hot water for at least 15 minutes, the green tea leaf powder is removed by filtration under reduced pressure and 4 ℃ After cooling to a precipitate to form a green tea extract by filtration under reduced pressure, spray drying and pulverizing the green tea extract, adding ethyl ether to the green tea extract and stirring to remove the ether layer A method for preparing green tea extract is provided.
녹차를 기호품으로 음용할 때에는 일반적으로 60-80℃의 물에 3-5분 동안 우려내어 사용하지만, 본 발명 추출물의 유효 성분인 폴리페놀은 유리되는데 더 많은 시간과 격렬한 조건을 요구한다. 따라서, 본 발명에서는 60-110℃의 열수에서 건조 녹차잎 분말 또는 생 녹차잎을 15분 이상 끓여서 추출하고, 4℃로 냉각시켜 침전물을 여과제거하여 수득된 추출액을 건조 및 분쇄한 후, 유기 용매로 다시 추출하여 유기용매에 용해성이 높은 물질을 제거한다.When drinking green tea as a favorite product, it is generally used for 3-5 minutes in water of 60-80 ° C., but the polyphenol, which is an active ingredient of the extract of the present invention, requires more time and intense conditions. Therefore, in the present invention, the dried green tea leaf powder or raw green tea leaf is extracted by boiling at least 15 minutes in hot water of 60-110 ℃, cooled to 4 ℃ to filter and remove the precipitate obtained by drying and grinding the organic solvent Extraction again to remove highly soluble substances in organic solvents.
제조된 추출물은 수성 추출액을 그대로 사용되거나, 제제화 및 복용의 편의를 위해 건조 분쇄하여 분말 형태로 사용될 수 있다.The prepared extract can be used as it is or in the form of powder by dry grinding for convenience of formulation and taking.
본 발명에 따르면, 전분이 이당류로 분해되는 단계의 효소인 아밀라제를 억제하는 작용을 가진 제제로서, 이당류가 증가되어 나타나는 설사나 장내 개스생성증가 등의 부작용이 나타나지 않는 혈당강하제로서, 상기 녹차 추출물은 혈당강하제에 함유된다.According to the present invention, as a preparation having the action of inhibiting amylase, an enzyme in the step of starch is broken down into disaccharides, as a hypoglycemic agent that does not exhibit side effects such as diarrhea and increased intestinal gas production, the disaccharide is increased, the green tea extract is It is contained in hypoglycemic agents.
또한, 본 발명의 방법에 따라 제조된 녹차 추출물은 중성지질의 소화 흡수감소에 의한 혈중 중성지질 감소 및 체지방의 감소 효과가 있으며, 혈중 콜레스테롤 감소효과가 있으므로, 본 발명에 따르면 상기 추출물은 고지혈증 치료제, 고콜레스테롤혈증 치료제 및 비만 치료제에 함유된다.In addition, the green tea extract prepared according to the method of the present invention has the effect of reducing triglyceride in blood and body fat by reducing digestive absorption of triglycerides, and reducing cholesterol in the blood, according to the present invention, the extract is used for treating hyperlipidemia, high It is contained in the treatment of hypercholesterolemia and in the treatment of obesity.
본 발명의 방법에 따른 녹차 추출물은 통상의 제제형태로 만들어져 경구 또는 비경구로 투여될 수 있다. 투여 형태는 특별히 제한되는 것은 아니지만, 보다 바람직하게는, 액제, 분말제, 캡슐, 정제, 시럽 등의 형태로 경구 투여되는 것이 좋다.Green tea extract according to the method of the present invention may be made in a conventional formulation and administered orally or parenterally. The dosage form is not particularly limited, but is more preferably administered orally in the form of a liquid, powder, capsule, tablet, syrup and the like.
본 발명에 따른 녹차 추출물 제제는 천연의 식품으로부터 추출되었으므로 인체에 독성이 없으며, 투여량은 투여목적 및 환자의 상태, 연령, 체중 등에 따라 적절히 조절될 수 있으나, 건조 추출물의 경우, 성인 1일당 투여량이 수백 mg 내지 수 g 정도, 추출액의 경우, 성인 1일당 투여량 수 ml 내지 수백 ml 정도에서 적절히 선택될 수 있다.Since the green tea extract preparation according to the present invention is extracted from natural foods, it is not toxic to the human body, and the dosage may be appropriately adjusted according to the purpose of administration and the condition, age, and weight of the patient, but in the case of the dry extract, it is administered per adult The amount may suitably be selected from several hundred mg to several g, and in the case of extracts, from several ml to several hundred ml per adult.
실시예Example
본 발명을 이하의 실시예를 들어 더욱 상세히 설명한다. 그러나, 본 발명은 이들 실시예에 국한되는 것은 아니다.The present invention will be described in more detail with reference to the following examples. However, the present invention is not limited to these examples.
실시예 1: 녹차추출물의 제조Example 1: Preparation of Green Tea Extract
열풍건조 녹차잎 분말 1Kg에 증류수 10 리터를 가하고, 30분 동안 환류 하에 가열하였다. 녹차잎 분말을 감압여과에 의해 제거하고, 4℃에서 1시간 동안 방치한 후 감압여과하여 추출액 8.5 리터를 수득하였다. 수득된 추출액(8.5L)를 분무건조하고 분쇄하여 230g의 녹차추출물 분말을 얻어, 에틸 에테르(500 ml)를 가하여 30분간 교반하여 에테르 층을 제거하였다.10 liters of distilled water was added to 1 Kg of hot air dried green tea leaf powder, and heated under reflux for 30 minutes. The green tea leaf powder was removed by filtration under reduced pressure, and left at 4 ° C. for 1 hour, followed by filtration under reduced pressure to obtain 8.5 liters of the extract. The obtained extract (8.5 L) was spray dried and pulverized to obtain 230 g of green tea extract powder. Ethyl ether (500 ml) was added thereto, followed by stirring for 30 minutes to remove the ether layer.
상기 수득된 녹차추출물(210g)을 건조시키고, 건조된 추출물을 분쇄하여 200 g의 녹차 추출물(A)을 수득하였다.The obtained green tea extract (210 g) was dried, and the dried extract was ground to obtain 200 g of green tea extract (A).
수득된 본 발명의 녹차 추출물(A)에 대하여 다음과 같은 방법으로 성분을 분석하였다.About the green tea extract (A) of the present invention obtained, the components were analyzed in the following manner.
성분분석Component Analysis
·유리아미노산: 닌히드린 발색법으로 발색하여 570nm에서 측정Free amino acid: measured at 570 nm by color development using ninhydrin
·유리당: HPLC법Free sugar: HPLC method
·카페인: HPLC법Caffeine: HPLC method
·무기이온: 분자흡광광도계Inorganic ion: Molecular absorbance photometer
·폴리펜놀: 프러시안 블루(Prussian blue)법에 의한 분광학적 산화환원 분석법(Spectrophotometric redox assay)Polyphenol: Spectrophotometric redox assay by Prussian blue
수득된 녹차 추출물의 성분 분석 결과는 다음과 같다.The result of component analysis of the obtained green tea extract is as follows.
실시예 2: 녹차추출물의 아밀라제 억제효과Example 2: Amylase Inhibitory Effect of Green Tea Extract
A. 전분부하실험A. Starch Load Experiment
체중이 220 내지 250 g인 스프라그-돌리(Splague-Dowley) 웅성 흰쥐를 사용하여 실험하였다.Experiments were performed using Splague-Dowley male rats weighing 220-250 g.
실험동물을 12 시간 동안 절식시킨 후, 각 군당 5마리씩의 대조군, 전분투여군, 전분과 녹차추출물 동시투여군으로 분류하여, 대조군에는 수돗물(3 ml)을, 전분투여군에는 전분 1g 과 수돗물에 용해시킨 혼합물(3 ml)을, 동시투여군에는 전분 1g과 실시예 1에서 제조된 녹차추출물(A)(60mg)를 수돗물에 용해시킨 혼합물(3ml)을 투여하였다.After fasting the experimental animals for 12 hours, each group was divided into 5 control groups, starch administration group, starch and green tea extract administration group, and mixed with tap water (3 ml) in the control group and 1 g of starch and tap water in the starch administration group. (3 ml), the co-administration group was administered a mixture (3 ml) in which 1 g of starch and green tea extract (A) (60 mg) prepared in Example 1 were dissolved in tap water.
40분 경과 후, 꼬리를 절개하고 채혈하여 혈당량을 측정하였다.After 40 minutes, the tail was dissected and blood collected to measure blood glucose levels.
결과를 하기 표 1에 나타낸다.The results are shown in Table 1 below.
(수치 = 평균값 ±표준편차)(Value = mean value ± standard deviation)
B. 엿당부하실험B. Sugar load test
체중이 220 내지 250 g인 스프라그-돌리(Splague-Dowley) 웅성 흰쥐를 사용하여 실험하였다.Experiments were performed using Splague-Dowley male rats weighing 220-250 g.
실험동물을 12 시간 동안 절식시킨 후, 각 군당 5마리씩의 대조군, 엿당투여군, 엿당과 녹차추출물 동시투여군으로 분류하여, 대조군에는 수돗물(3 ml)을, 엿당투여군에는 엿당 1g을 수돗물에 용해시킨 혼합물(3 ml)을, 동시투여군에는 엿당 1g과 실시예 1에서 제조된 녹차추출물(A)(60 mg)을 수돗물에 용해시킨 혼합물(3ml)을 투여하였다.After fasting the experimental animals for 12 hours, each group was divided into 5 controls, maltose administration group, maltose and green tea extract simultaneous administration group, and mixed with tap water (3 ml) in the control group and 1 g of maltose in the maltose administration group in tap water. (3 ml), the co-administration group was administered with a mixture (3 ml) of 1 g of malt and green tea extract (A) prepared in Example 1 (60 mg) dissolved in tap water.
40분 경과 후, 꼬리를 절개하고 채혈하여 혈당량을 측정하였다.After 40 minutes, the tail was dissected and blood collected to measure blood glucose levels.
결과를 하기 표 2에 나타낸다.The results are shown in Table 2 below.
(수치 = 평균값 ±표준편차)(Value = mean value ± standard deviation)
C. 포도당 부하실험C. Glucose Load Test
체중이 220 내지 250 g인 스프라그-돌리(Splague-Dowley) 웅성 흰쥐를 사용하여 실험하였다.Experiments were performed using Splague-Dowley male rats weighing 220-250 g.
실험동물을 12 시간 동안 절식시킨 후, 각 군당 5마리씩의 대조군, 포도당투여군, 포도당과 녹차추출물 동시투여군으로 분류하여, 대조군에는 수돗물(3 ml)을, 포도당 투여군에는 포도당 1g을 수돗물에 용해시킨 혼합물(3 ml)을, 동시투여군에는 포도당 1g과 실시예 1에서 제조된 녹차추출물(A)(60mg)을 용해시킨 혼합물(3ml)을 투여하였다.After fasting the experimental animals for 12 hours, each group was divided into 5 control groups, glucose administration group, glucose and green tea extract simultaneous administration group, and a mixture of tap water (3 ml) in the control group and 1 g of glucose in the glucose administration group was dissolved in tap water. (3 ml), the co-administration group was administered a mixture (3 ml) in which 1g of glucose and green tea extract (A) (60 mg) prepared in Example 1 were dissolved.
40분 경과 후, 꼬리를 절개하고 채혈하여 혈당량을 측정하였다.After 40 minutes, the tail was dissected and blood collected to measure blood glucose levels.
결과를 하기 표 3에 나타낸다.The results are shown in Table 3 below.
(수치 = 평균값 ±표준편차)(Value = mean value ± standard deviation)
실시예 3: 당뇨병 쥐에서 미치는 녹차추출물의 혈당강하 작용Example 3: Hypoglycemic Action of Green Tea Extract in Diabetic Rats
체중이 220 내지 250 g인 스프라그-돌리(Splague-Dowley) 웅성 흰쥐를 사용하여 실험하였다.Experiments were performed using Splague-Dowley male rats weighing 220-250 g.
실험동물을 12 시간 동안 절식시킨 후, 알록산(Alloxan)을 생리식염수에 용해시켜 흰쥐의 체중 1 kg당 80 mg의 양으로 주사하여 당뇨병을 유발하였다. 당뇨병이 유발된 흰쥐를 7일간 사육한 후 혈당량이 400mg/100ml혈액 이상인 흰쥐를 당뇨병 흰쥐로 실험에 사용하였다. 각 군당 5 마리씩 대조군 및 녹차 추출물 투여군으로 분류하여, 대조군에는 정상 식이를, 녹차 추출물 투여군에는 녹차 추출물(A)(40g)를 사료(1 kg)에 첨가하여 재조합한 같은 사료를 주어 사육하였다.After fasting the experimental animals for 12 hours, alloxan was dissolved in physiological saline and injected with an amount of 80 mg / kg of rats to induce diabetes. Diabetic rats were bred for 7 days, and then rats with blood glucose above 400 mg / 100ml were used as diabetic rats. Five animals in each group were divided into the control group and the green tea extract administration group, and the control group was fed with the same diet recombined with the normal diet and the green tea extract administration group with the green tea extract (A) (40 g) added to the feed (1 kg).
일정한 시간의 경과 후, 각군 동물의 꼬리를 절개하고 채혈하여 혈당량을 측정하였다.After a certain period of time, the blood glucose levels were measured by dissecting the tails of each group of animals and collecting blood.
실험 결과는 하기 표 4에 나타낸다.The experimental results are shown in Table 4 below.
(수치 = 평균값 ± 표준편차)(Value = mean value ± standard deviation)
실시예 4: 녹차추출물의 혈당감소 효과Example 4 Blood Sugar Reduction Effect of Green Tea Extract
공복시 혈당이 200 내지 250mg/100ml 혈액인 10명의 자원자에 대하여 혈당량을 측정하였다.Blood glucose levels were measured for 10 volunteers with fasting blood glucose levels between 200 and 250 mg / 100 ml of blood.
실시예 1에서 수득된 건조 녹차 추출물(A)을 매 식사 중 (1일 3회) 1 g씩 6주간 투여하였다.The dried green tea extract (A) obtained in Example 1 was administered for 1 week at 1 g each meal (3 times a day).
1주간격으로 5주간 식전과 식사후 2시간에 혈액을 체취하여 혈당량을 측정하였다.Blood glucose levels were measured by taking blood for 5 weeks before meals and 2 hours after meals at 1 week intervals.
실험 결과는 하기 표 5 에 나타낸다.The experimental results are shown in Table 5 below.
(수치 = 평균값 ± 표준편차)(Value = mean value ± standard deviation)
실시예 5: 녹차추출물의 중성지질 감소 및 체중 감소 효과Example 5: Neutral Lipid Reduction and Weight Loss Effect of Green Tea Extract
비만으로 판정된(BMI 30이상) 10명의 자원자에 대하여 체중가 혈당 및 혈중 중성지질량을 측정하였다.Body weights of blood glucose and blood triglycerides were measured for 10 volunteers who were determined to be obese (over 30 BMI).
실시예 1에서 수득된 건조 녹차 추출물(A)을 매 식사 중 (1일 3회) 1 g씩 4주간 투여하였다.The dried green tea extract (A) obtained in Example 1 was administered for 1 week at 1 g each meal (three times a day).
매주 체중을 측정하고 2주 간격으로 혈액을 체취하여 혈당과 혈청의 중성지질량을 측정하였다.Body weights were measured weekly and blood was collected at two week intervals to determine the mass of blood glucose and serum neutral fat.
실험결과를 하기 표 6에 나타낸다.The experimental results are shown in Table 6 below.
(수치: 평균값)(Numeric value)
실시예 6: 녹차추출물의 중성지질 감소 효과Example 6 Neutral Lipid Reduction Effect of Green Tea Extract
혈중 중성지질량이 200내지 300mg/100ml인 10명의 자원자에 대하여 혈중 중성지질량을 측정하였다.Blood neutral mass was measured for 10 volunteers whose blood neutral mass was 200 to 300 mg / 100 ml.
실시예 1에서 수득된 건조 녹차 추출물(A)을 매 식사 중 (1일 3회) 750mg씩 4주간 투여하였다.The dried green tea extract (A) obtained in Example 1 was administered for 4 weeks in 750 mg of each meal (3 times a day).
1주 간격으로 4주간 식전에 혈액을 체취하여 중성지질량을 측정하였다.Blood was collected before meals for 4 weeks at weekly intervals and the mass of neutral fat was measured.
실험 결과는 하기 표 7에 나타낸다.The experimental results are shown in Table 7 below.
(수치 = 평균값 ± 표준편차)(Value = mean value ± standard deviation)
실시예 7: 녹차추출물의 콜레스테롤 감소 효과Example 7: Cholesterol Reduction Effect of Green Tea Extract
혈중 콜레스테롤량이 260내지 350mg/100ml인 10명의 자원자에 대하여 혈중 콜레스테롤량을 측정하였다.Blood cholesterol levels were measured in 10 volunteers with blood cholesterol levels of 260 to 350 mg / 100ml.
실시예 1에서 수득된 건조 녹차 추출물(A)을 매 식사 후 (1일 3회) 750mg씩4주간 투여하였다.The dried green tea extract (A) obtained in Example 1 was administered for 4 weeks after 750 mg of each meal (three times a day).
1주간격으로 6주간 식전에 혈액을 체취하여 콜레스테롤량을 측정하였다.Blood was collected before meals for 6 weeks at weekly intervals and cholesterol levels were measured.
실험 결과는 하기 표 8에 나타낸다.The experimental results are shown in Table 8 below.
(수치 = 평균값 ± 표준편차)(Value = mean value ± standard deviation)
실시예8: 녹차 추출물의 간 및 신장독성시험Example 8 Liver and Kidney Toxicity Test of Green Tea Extract
체중이 220 내지 250g인 스프라그-돌리(Splague-Dowley) 웅성 흰쥐를 사용하여 실험하였다.Experiments were conducted using Splague-Dowley male rats weighing 220-250 g.
실험동물을 12 시간 동안 절식시킨 후, 각 군당 10마리씩의 대조군, 녹차추출물 투여군으로 분류하여, 대조군에는 수돗물(2 ml)을, 녹차추출물 투여군에는 실시예 1에서 수득된 녹차추출물(A)(100mg)을 수돗물(2ml)에 용해시켜 경구 투여하였다.After fasting the experimental animals for 12 hours, each group was divided into 10 control groups, green tea extract administration group, tap water (2 ml) in the control group, green tea extract (A) obtained in Example 1 in the green tea extract administration group (100 mg) ) Was dissolved in tap water (2 ml) and administered orally.
1일 경과 후, 흰쥐를 희생시켜 복부동맥에서 채혈하여 혈당과 BUN, sGOT, sGPT, 알칼린 포스파타제 및 크레아틴의 양을 혈액 생화학 분석장비를 이용하여 각각 측정하였다.After 1 day, rats were sacrificed and blood was collected from the abdominal artery, and blood glucose, BUN, sGOT, sGPT, alkaline phosphatase, and creatine were measured using blood biochemical analyzers, respectively.
결과를 하기 표 9에 나타낸다.The results are shown in Table 9 below.
(수치 = 평균값 ± 표준편차)(Value = mean value ± standard deviation)
상기 실험 결과에 나타난 바와 같이 녹차 추출물을 투여한 쥐에서 간이나 신장에 대한 독성은 나타나지 않았다.As shown in the experimental results, there was no toxicity to liver or kidney in the rats to which the green tea extract was administered.
상기 실시예의 실험결과들로부터 나타난 바와 같이, 본 발명에 따르는 녹차 추출물은 전분이 이당류로 분해되는 단계에 관여하는 효소인 아밀라제를 억제하는 작용을 가지므로 전분의 소화를 억제하여 당뇨병 환자의 혈당량을 감소시키는 작용이 있다. 따라서, 본 발명의 제제를 투여함으로써 당뇨병 환자의 혈당 증가를 억제시킬 목적으로 요구되고 있는 완고한 식사요법을 완화시켜 정상적인 식사를 하면서도 혈당량을 감소시키는 것이 가능하다.As shown from the experimental results of the above embodiment, the green tea extract according to the present invention has an action of inhibiting amylase, an enzyme involved in the step of starch decomposing into disaccharides, thereby inhibiting starch digestion and reducing blood glucose levels in diabetic patients. There is a function to let. Therefore, by administering the preparation of the present invention, it is possible to alleviate the stubborn meal therapy, which is required for the purpose of suppressing the increase in blood sugar of diabetic patients, and to reduce the blood sugar level while eating a normal meal.
또한, 본 발명의 녹차 추출물은 혈중 중성지질량과 콜레스테롤량을 감소시키는 효과가 있으므로 고지혈증과 고콜레스테롤혈증 치료제로서 유용하며, 체지방을 감소시켜 체중 조절, 비만 예방 및 치료에 적절하게 사용될 수 있다.이상 설명한 내용을 통해 당업자라면 본 발명의 기술사상을 일탈하지 아니하는 범위에서 다양한 변경 및 수정이 가능함을 알 수 있을 것이다. 따라서, 본 발명의 기술적 범위는 명세서의 상세한 설명에 기재된 내용으로 한정되는 것이 아니라 특허 청구의 범위에 의해 정하여 져야만 할 것이다.In addition, the green tea extract of the present invention is effective as a therapeutic agent for hyperlipidemia and hypercholesterolemia because it has an effect of reducing the amount of triglyceride and cholesterol in the blood, and can be suitably used for weight control, obesity prevention and treatment by reducing body fat. Those skilled in the art will appreciate that various changes and modifications can be made without departing from the spirit of the present invention. Therefore, the technical scope of the present invention should not be limited to the contents described in the detailed description of the specification but should be defined by the claims.
Claims (6)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2000-0014644A KR100377313B1 (en) | 2000-03-22 | 2000-03-22 | Method Of Fabricating Green tea Extractive |
| PCT/KR2001/000463 WO2001076382A1 (en) | 2000-03-22 | 2001-03-22 | Method of extracting the staple ingredients from camellia sinensis including polyphenols, and the medicine for diabetes, hyperlipemia, hypercholesterinemia, obesity and hypertension having the extract of camellia sinesis as principal components |
| AU44771/01A AU4477101A (en) | 2000-03-22 | 2001-03-22 | Method of extracting the staple ingredients from camellia sinensis including polyphenols, and the medicine for diabetes, hyperlipemia, hypercholesterinemia, obesity and hypertension having the extract of camellia sinesis as principal components |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2000-0014644A KR100377313B1 (en) | 2000-03-22 | 2000-03-22 | Method Of Fabricating Green tea Extractive |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR10-2002-0036016A Division KR100407036B1 (en) | 2002-06-26 | 2002-06-26 | Remedy For Hypoglycemic Agent Contained With Green tea Extractive |
| KR10-2002-0036017A Division KR100407037B1 (en) | 2002-06-26 | 2002-06-26 | Remedy For Obesity Therapy Contained With Green Tea Extractive |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20000030866A KR20000030866A (en) | 2000-06-05 |
| KR100377313B1 true KR100377313B1 (en) | 2003-03-26 |
Family
ID=19657645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR10-2000-0014644A KR100377313B1 (en) | 2000-03-22 | 2000-03-22 | Method Of Fabricating Green tea Extractive |
Country Status (3)
| Country | Link |
|---|---|
| KR (1) | KR100377313B1 (en) |
| AU (1) | AU4477101A (en) |
| WO (1) | WO2001076382A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004105679A2 (en) * | 2003-05-30 | 2004-12-09 | Matthias Rath | Use of a nutritional composition for treating hypertension |
| FR2879596B1 (en) * | 2004-12-17 | 2007-08-10 | Elysee Lab | PROCESS FOR OBTAINING STABILIZED NATURAL POLYPHENOLS, POLYPHENOLS OBTAINED THEREBY, AND USE OF THESE POLYPHENOLS IN CARBOHYDRATE METABOLISM |
| DE102006045762A1 (en) * | 2006-09-26 | 2008-04-10 | Plantextrakt Gmbh & Co. Kg | Green tea drug extract, in particular for the prophylaxis and treatment of diseases of the central nervous system, its use for the production of a medicament and process for its preparation |
| KR101965591B1 (en) * | 2012-11-21 | 2019-04-04 | (주)아모레퍼시픽 | Composition for inhibiting activity of amylase containing chitooligosaccharide |
| SI2938350T1 (en) * | 2012-12-27 | 2019-05-31 | Taal-Vlas, Anita Monique | Medical formulation for treating hypercholesterolemia |
| KR101302154B1 (en) * | 2013-02-27 | 2013-08-30 | 강원대학교산학협력단 | Cubic phase nanoparticle and herbal extracts mixture suspension exhibiting enhanced anti-obesity efficacy and method for preparing the same |
| CN109924295A (en) * | 2017-12-17 | 2019-06-25 | 江苏珍香生态农业科技有限公司 | A kind of production technology of health-care type green tea |
| CN114904293A (en) * | 2022-05-05 | 2022-08-16 | 泉州市金斗洋生态农业股份有限责任公司 | Batch recycling and extracting process for oolong tea leaves |
| CN116138289A (en) * | 2023-03-24 | 2023-05-23 | 上海来伊份股份有限公司 | Low-GI bread and preparation method thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR960010608B1 (en) * | 1993-09-10 | 1996-08-06 | 재단법인 한국인삼연초연구원 | Manufacturing method of green tea |
| KR970005233B1 (en) * | 1994-07-01 | 1997-04-14 | 주식회사 태평양 | Method for preparing tea |
| KR19980072441A (en) * | 1997-03-05 | 1998-11-05 | 손경식 | Composition for α-wave enhanced beverage Beverage containing the same |
| KR100213830B1 (en) * | 1997-03-20 | 1999-08-02 | 김동태 | Green tea |
-
2000
- 2000-03-22 KR KR10-2000-0014644A patent/KR100377313B1/en not_active IP Right Cessation
-
2001
- 2001-03-22 AU AU44771/01A patent/AU4477101A/en not_active Abandoned
- 2001-03-22 WO PCT/KR2001/000463 patent/WO2001076382A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| KR20000030866A (en) | 2000-06-05 |
| AU4477101A (en) | 2001-10-23 |
| WO2001076382A1 (en) | 2001-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2657757C2 (en) | Novel extracts of cynara scolymus, coffea spp. and olea europaea for the treatment of metabolic syndrome | |
| EP1300084B1 (en) | Composition for the treatment of chronic venous insufficiencies comprising an extract of red vine leaves | |
| KR100377313B1 (en) | Method Of Fabricating Green tea Extractive | |
| KR20110033644A (en) | Composition for curing hangover and method manufacturing thereof | |
| JPH07274894A (en) | Food/beverage for preventing gastric ulcer | |
| US5741491A (en) | Medicinal composition for diabetes | |
| WO2007100103A1 (en) | Ameliorating agent for metabolic syndrome | |
| WO2006030426A1 (en) | Herbal compositions for treatment of diabetes | |
| KR100577677B1 (en) | Composition for lowering blood glucose | |
| KR100407037B1 (en) | Remedy For Obesity Therapy Contained With Green Tea Extractive | |
| JP4043645B2 (en) | Yacon and mulberry leaves | |
| JPH04266828A (en) | Plant extract and its use | |
| KR100407036B1 (en) | Remedy For Hypoglycemic Agent Contained With Green tea Extractive | |
| KR100496622B1 (en) | Alcohol fermented food or pharmaceutical composition for prevention of obesity and process for preparation thereof | |
| KR101796924B1 (en) | Composition for improving hepatic function containing ginseng berry extracts | |
| US5516516A (en) | Method of preparing muira puama extract and its use for decreasing body fat percentage and increasing lean muscle mass | |
| KR102588372B1 (en) | Composition comprising natural complex extract for prenenting, improving or treating gastritis and peptic ulcer | |
| JP2955679B2 (en) | Ethanol metabolism promoter | |
| JP2006257018A (en) | Antiobestic agent, medicine and beverage or food | |
| JP2007063130A (en) | Anti-diabetic composition | |
| KR0179088B1 (en) | Composition containing rhodiola sachalinesis extract for prophylaxis and treatment of diabetes mellitus | |
| KR0179087B1 (en) | Composition containing rhodiola sachalinesis extract for lowering blood alcohol concentration | |
| KR20090126469A (en) | The herb extract composition for the blood glucose reducing action | |
| KR101398715B1 (en) | Hypoglycemic composition containing component originating in the bark of tree belonging to the genus acacia | |
| KR20170109881A (en) | Remedy For Obesity Therapy Contained With Green TeaExtractive |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| A107 | Divisional application of patent | ||
| E902 | Notification of reason for refusal | ||
| A107 | Divisional application of patent | ||
| E701 | Decision to grant or registration of patent right | ||
| N231 | Notification of change of applicant | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20060201 Year of fee payment: 6 |
|
| LAPS | Lapse due to unpaid annual fee |